Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems*
暂无分享,去创建一个
David Siegel | David Ross | J. Pietenpol | Luojia Tang | D. Ross | A. Anwar | D. Dehn | D. Siegel | J. Kepa | Adil Anwar | Donna Dehn | Jadwiga K Kepa | Luo Jia Tang | Jennifer A Pietenpol | Donna L. Dehn
[1] Yoichi Taya,et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 , 2002, Nature Cell Biology.
[2] T. Naoe,et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] L. Neckers,et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.
[4] L. Amzel,et al. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.
[5] D. Ross,et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). , 1997, British Journal of Cancer.
[6] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[7] D. Ross,et al. DT-diaphorase in activation and detoxification of quinones , 1993, Cancer and Metastasis Reviews.
[8] J. Lear,et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. , 1999, Carcinogenesis.
[9] D. Lane,et al. The p53 tumour suppressor gene , 1998, The British journal of surgery.
[10] D. Ross,et al. Interaction of the Molecular Chaperone Hsp70 with Human NAD(P)H:Quinone Oxidoreductase 1* , 2002, The Journal of Biological Chemistry.
[11] J. Pietenpol,et al. Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[12] L. Landi,et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[13] K. Danenberg,et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. , 1992, Cancer research.
[14] T. Ebert,et al. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. , 1997, Pharmacogenetics.
[16] Z. Ronai,et al. p53-Mdm2--the affair that never ends. , 2002, Carcinogenesis.
[17] K. Vousden. Activation of the p53 tumor suppressor protein. , 2002, Biochimica et biophysica acta.
[18] J. Pietenpol,et al. p53 Signaling and cell cycle checkpoints. , 2001, Chemical research in toxicology.
[19] D. Ross,et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. , 2001, Molecular pharmacology.
[20] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[21] P. Talalay,et al. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[22] Lars Ernster. [56] DT diaphorase , 1967 .
[23] K. Tew,et al. Glutathione S-transferase P1–1 (GSTP1–1) Inhibits c-Jun N-terminal Kinase (JNK1) Signaling through Interaction with the C Terminus* , 2001, The Journal of Biological Chemistry.
[24] D. Ross,et al. A note on the inhibition of DT-diaphorase by dicoumarol. , 1991, Free radical biology & medicine.
[25] J. Milner,et al. The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage , 2002, Oncogene.
[26] J. Heath,et al. Hyaluronidase Induction of a WW Domain-containing Oxidoreductase That Enhances Tumor Necrosis Factor Cytotoxicity* , 2001, The Journal of Biological Chemistry.
[27] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[28] M. Pincus,et al. Regulation of JNK signaling by GSTp , 1999, The EMBO journal.
[29] D. Liebler,et al. The Reduction of α-Tocopherolquinone by Human NAD(P)H:Quinone Oxidoreductase: The Role of α-Tocopherolhydroquinone as a Cellular Antioxidant , 1997 .
[30] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[31] H. Kawai,et al. Dual Role of p300 in the Regulation of p53 Stability* , 2001, The Journal of Biological Chemistry.
[32] S. Müller,et al. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Merchant,et al. ZBP-89 Promotes Growth Arrest through Stabilization of p53 , 2001, Molecular and Cellular Biology.
[34] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. Morgan,et al. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. , 2001, Blood.
[36] M F Greaves,et al. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. , 1999, Cancer research.
[37] Ted R. Hupp,et al. Strategies for manipulating the p53 pathway in the treatment of human cancer , 2000 .
[38] D. Ross,et al. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. , 1999, Pharmacogenetics.
[39] K. Vousden,et al. Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.
[40] C. Huggins,et al. INDUCED PROTECTION OF ADRENAL CORTEX AGAINST 7,12-DIMETHYLBENZ[a]ANTHRACENE , 1964, The Journal of Experimental Medicine.
[41] D. Lane,et al. Cancer: Awakening angels , 1998, Nature.
[42] D. Ross,et al. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. , 1994, Cancer research.
[43] D. Labuda,et al. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia , 2002, International journal of cancer.
[44] K. Tew,et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. , 2001, The Journal of pharmacology and experimental therapeutics.
[45] D. Roop,et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. , 2000, Cancer research.
[46] M. Żylicz,et al. Co‐chaperones Bag‐1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild‐type or mutant p53 , 2001, The EMBO journal.
[47] F. King,et al. Hsp70 interactions with the p53 tumour suppressor protein , 2001, The EMBO journal.
[48] L. Ernster,et al. DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. , 1982, Archives of biochemistry and biophysics.
[49] J. Lotem,et al. NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Roop,et al. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. , 2001, Journal of the National Cancer Institute.
[51] S. Orrenius,et al. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. , 1982, The Journal of biological chemistry.